Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Sandler

Showing results (11-20 of 117) with videos related to

Pageof 12
Sort By:
JAMA Oncology|July 17, 2015
Watchful Waiting-Active Surveillance in Low-Risk Prostate CancerBruce G Haffty, Colleen A F Lawton, Howard Sandler
The Canadian Journal of Urology|May 16, 2002
Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United StatesRichard Choo, Howard Sandler, Padraig Warde, et al.
Annals of Internal Medicine|April 21, 2018
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO TrialsJoin Y Luh, Steven E Finkelstein, Jeff M Michalski, et al.
Urologic Oncology|May 29, 2021
Outcomes with brachytherapy based dose escalation for gleason 8 versus 9-10 prostate cancer: An NCDB analysisJohn David, Michael Luu, Diana Lu, et al.
International Journal of Radiation Oncology, Biology, Physics|June 28, 2003
A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancerRobert Takamiya, Vivian Weinberg, C Dale Young, et al.
International Journal of Radiation Oncology, Biology, Physics|March 7, 2013
Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancerFelix Y Feng, Kevin Blas, Karin Olson, et al.
International Journal of Radiation Oncology, Biology, Physics|May 13, 2023
Beyond Diversity Toward Inclusion, Belonging, and SafetyIris C Gibbs, Geraldine Jacobson, Laura Dawson, et al.
International Journal of Radiation Oncology, Biology, Physics|March 19, 2011
Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06Richard K Valicenti, Kwounghwa Bae, Jeff Michalski, et al.
European Urology|July 1, 2023
Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 StudiesFelix Feng, Branko Miladinovic, Ke Zhang, et al.
Practical Radiation Oncology|March 14, 2014
Dosimetric analysis of radiation therapy oncology group 0321: the importance of urethral doseI-Chow Hsu, Daniel Hunt, William Straube, et al.
Pageof 12

Showing results (11-20 of 117) with videos related to

Sort By:
Pageof 12
JAMA Oncology|July 17, 2015
Watchful Waiting-Active Surveillance in Low-Risk Prostate CancerBruce G Haffty, Colleen A F Lawton, Howard Sandler
The Canadian Journal of Urology|May 16, 2002
Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United StatesRichard Choo, Howard Sandler, Padraig Warde, et al.
Annals of Internal Medicine|April 21, 2018
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO TrialsJoin Y Luh, Steven E Finkelstein, Jeff M Michalski, et al.
Urologic Oncology|May 29, 2021
Outcomes with brachytherapy based dose escalation for gleason 8 versus 9-10 prostate cancer: An NCDB analysisJohn David, Michael Luu, Diana Lu, et al.
International Journal of Radiation Oncology, Biology, Physics|June 28, 2003
A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancerRobert Takamiya, Vivian Weinberg, C Dale Young, et al.
International Journal of Radiation Oncology, Biology, Physics|March 7, 2013
Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancerFelix Y Feng, Kevin Blas, Karin Olson, et al.
International Journal of Radiation Oncology, Biology, Physics|May 13, 2023
Beyond Diversity Toward Inclusion, Belonging, and SafetyIris C Gibbs, Geraldine Jacobson, Laura Dawson, et al.
International Journal of Radiation Oncology, Biology, Physics|March 19, 2011
Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06Richard K Valicenti, Kwounghwa Bae, Jeff Michalski, et al.
European Urology|July 1, 2023
Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 StudiesFelix Feng, Branko Miladinovic, Ke Zhang, et al.
Practical Radiation Oncology|March 14, 2014
Dosimetric analysis of radiation therapy oncology group 0321: the importance of urethral doseI-Chow Hsu, Daniel Hunt, William Straube, et al.
Pageof 12